Healthcare News: Weekly Roundup for May 23 to 30, 2026

Eli Lilly closed the week by committing up to $3.8 billion to buy three vaccine developers at once, the clearest signal yet that the company plans to spend its obesity-drug windfall on infectious disease. That single move framed seven days of dense activity, and it sits at the center of this week’s healthcare news for May 23 to 30, 2026.

Regulators on three continents cleared new therapies, European reviewers backed the first oral GLP-1 for weight management, and the World Health Organization declared a rare Ebola strain a global emergency.

For clinicians tracking drug approvals, investors scanning biotech funding, and hospital leaders watching policy, this week’s healthcare news rewarded close reading. What follows are the twelve stories that mattered most across the United States, the United Kingdom, Canada, Australia, Europe, and beyond.

Here are the top trending healthcare news headlines for the week:

1. Eli Lilly spends up to $3.8 billion on three vaccine makers
2. EMA backs the first oral semaglutide tablet for weight management
3. BeOne’s zanidatamab posts positive Phase 3 gastric cancer survival data
4. NHS England names its first six advanced foundation trusts
5. Health Canada clears Apotex’s IHEEZO ophthalmic anesthetic
6. Australia’s TGA approves orelabrutinib for mantle cell lymphoma
7. WHO declares a Bundibugyo Ebola outbreak a global emergency
8. CMS launches its BALANCE model to cap GLP-1 costs in Medicaid
9. Medtronic, Abbott, and Boston Scientific present new ablation data at HRS 2026
10. Gilead’s Hepcludex becomes the first approved hepatitis delta therapy
11. Early-stage biotechs close fresh Series A rounds despite a tight market
12. CDC widens a Salmonella alert tied to moringa leaf products

Eli Lilly Commits Up to $3.8 Billion to Acquire Three Vaccine Developers

Eli Lilly agreed on May 26 to acquire three vaccine companies in deals worth as much as $3.8 billion combined, a coordinated push into infectious disease prevention from a drugmaker best known for diabetes and obesity therapies. The targets are Curevo, LimmaTech Biologics, and a privately held firm referred to as Vaccine Company, and together they hand Lilly candidates aimed at shingles, common bacterial pathogens, and Epstein-Barr virus.

The structure of the agreements tells the story of how Lilly is valuing pipeline risk. The Curevo transaction is built to deliver shareholders as much as $1.5 billion, LimmaTech equity holders stand to collect up to $780 million, and the Vaccine Company is valued at as much as $1.55 billion in cash. Much of that upside is tied to development and regulatory milestones rather than paid upfront, which keeps Lilly’s downside contained if any single program stumbles. The move follows the company’s earlier hiring of former FDA vaccine regulator Peter Marks, a recruitment that now reads as a deliberate prelude to building a vaccine franchise.

For the wider market, this is a competitive signal as much as a strategic one. Lilly is deploying cash generated by booming demand for its incretin medicines to diversify away from a single therapeutic engine, and that gives it room to challenge entrenched vaccine players such as GSK, Pfizer, and Merck on shingles and EBV. Rivals chasing the same patent cliff math will read these three deals as a marker for how aggressively Big Pharma is willing to pay for late-stage and clinical vaccine assets in 2026. Patients could ultimately benefit from a more crowded shingles and EBV field, though the payoff depends on trials that have years left to run.

Source: Axios | https://www.axios.com/2026/05/26/eli-lilly-vaccines

EMA Recommends the First Oral Semaglutide Tablet for Weight Management

Europe’s medicines regulator handed the obesity market a structural change in late May when its Committee for Medicinal Products for Human Use recommended extending Wegovy’s marketing authorization to include a daily oral tablet. The opinion, issued after the committee’s May 18 to 21 meeting and publicized in the days that followed, makes oral semaglutide the first GLP-1 receptor agonist for weight management developed in pill form rather than as a weekly injection.

The recommendation came in a batch of eight new medicines and 13 indication extensions backed by the committee. Alongside Wegovy, reviewers issued a positive opinion for Jascayd, known generically as nerandomilast, for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, and recommended a conditional marketing authorization for Vijoice in patients with severe PIK3CA-related overgrowth spectrum disorders. The European Commission typically issues final decisions within two to three months of a committee opinion, so formal authorization should land in the third quarter.

The clinical implication of an oral GLP-1 is access, not novelty of mechanism. A swallowed tablet removes the needle barrier that keeps some patients away from injectable therapy and simplifies cold-chain logistics for pharmacies and payers across the European Union. That convenience could expand the treated population well beyond current injectable users, which is exactly why competitors developing their own oral incretins will watch European uptake closely. Health systems negotiating reimbursement, however, will weigh that broader demand against budgets already strained by injectable GLP-1 spending.

Source: European Medicines Agency | https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-may-2026

BeOne Medicines Reports Positive Phase 3 Gastric Cancer Survival Data in NEJM

BeOne Medicines published results from its HERIZON-GEA-01 Phase 3 trial in the New England Journal of Medicine on May 27, timed to a presentation at the 2026 American Society of Clinical Oncology annual meeting. The study tested zanidatamab, marketed as Ziihera, plus chemotherapy, with and without the company’s PD-1 inhibitor tislelizumab, against trastuzumab plus chemotherapy as a first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma.

Both zanidatamab-containing arms produced a statistically significant and clinically meaningful improvement in progression-free survival, with a median of 12.4 months reported in the trial. For a cancer where first-line options have leaned on trastuzumab-based regimens for years, a bispecific HER2-directed antibody showing superiority on the primary endpoint is a meaningful addition to the treatment conversation. The ASCO presentation placed the data in front of the oncology community at the moment regulators and guideline committees begin weighing whether the standard of care should shift.

The competitive stakes are considerable. HER2-positive gastroesophageal cancer is a contested space, and a positive head-to-head readout against the incumbent standard strengthens the commercial case for zanidatamab while pressuring trastuzumab-anchored regimens. The same ASCO meeting featured striking pancreatic cancer survival data for the RAS inhibitor daraxonrasib, where median overall survival reached 13.2 months versus 6.7 months for chemotherapy in the RASolute 302 trial, underscoring how quickly the first-line oncology field is being redrawn. Clinicians will want to see overall survival mature before changing practice, but the direction of travel is clear.

Source: BeOne Medicines | https://www.businesswire.com/news/home/20260527389623/en/BeOne-Medicines-Announces-Phase-3-HERIZON-GEA-Data-Published-in-NEJM-and-Presented-at-ASCO-2026

NHS England Names Its First Six Advanced Foundation Trusts

NHS England announced its first six advanced foundation trusts on May 27, the opening cohort in a new tier of provider that gains greater autonomy over budgets, staffing, and service design in return for strong operational performance. The designation arrives during a period of unusual structural upheaval for the English health service, which is being reshaped by the NHS Modernisation Bill introduced earlier in May.

That bill confirms the planned abolition of NHS England as an arm’s length body and the transfer of its functions into central government, a reversal of more than a decade of organizational design. The advanced foundation trust model fits into this redrawn system as a way to reward high-performing providers with freedom while the central architecture above them changes. The announcement also followed news that the service hit its 18-week waiting time target threshold in March, with the waiting list falling by more than 312,000 over the prior year, the largest annual reduction in 16 years.

For trust leaders, the practical question is what the new autonomy actually unlocks. Greater control over capital and workforce decisions could let the leading trusts move faster on hospital operations and recruitment, but it also raises the prospect of a widening gap between the best-performing organizations and those still struggling with backlogs. Patients in catchment areas served by an advanced trust may see faster access, while the reforms test whether devolved freedom improves outcomes without fragmenting a national system already managing a turbulent transition.

Source: NHS England | https://www.england.nhs.uk/news/

Health Canada Clears Apotex’s IHEEZO Ophthalmic Anesthetic

Health Canada approved IHEEZO, a chloroprocaine hydrochloride ophthalmic gel at 3 percent strength, on May 26, giving Canadian ophthalmologists a topical anesthetic indicated for ocular surface anesthesia during eye procedures in adults. The authorization went to Apotex and continues a busy stretch for the Toronto-based generics and specialty manufacturer, which has been widening its branded and ophthalmic portfolio alongside its core generics business.

The clearance lands in the same month Apotex became the first Canadian-based pharmaceutical company to win Health Canada authorization for a generic equivalent of Ozempic, and weeks after BioSyent secured approval for the first levothyroxine oral solution available in the country. Taken together, the approvals show a Canadian regulator working through a steady queue of both specialty branded products and cost-saving generics as patients and provincial drug plans look for affordability.

For ophthalmology practices, a gel-based anesthetic offers a handling profile that differs from drop formulations, which can matter for surface contact time during procedures. The broader signal sits with Apotex itself. A company long defined by generics is layering in specialty products that carry higher margins and clinical differentiation, a strategy that positions it to compete beyond price alone in the Canadian market. Provincial formularies will determine how quickly the product reaches operating rooms.

Source: PR Newswire | https://www.prnewswire.com/news-releases/apotex-expands-ophthalmic-portfolio-with-health-canada-approval-of-iheezo-302781762.html

Australia’s TGA Approves Orelabrutinib for Mantle Cell Lymphoma

The Therapeutic Goods Administration approved orelabrutinib, sold as Hibruka, in Australia on May 27, adding a treatment option for patients with relapsed or refractory mantle cell lymphoma. InnoCare Pharma, the biopharmaceutical company behind the BTK inhibitor, announced the clearance and described it as an expansion of its presence in the Australian oncology market.

Mantle cell lymphoma is a distinct and aggressive subtype of B-cell non-Hodgkin lymphoma with a rising incidence and no current cure, which leaves clinicians reliant on a rotation of targeted agents as patients relapse. A next-generation BTK inhibitor entering the Australian market gives hematologists another line of therapy for a disease where durable responses are difficult to sustain and where each additional option can extend the treatment runway for individual patients.

The approval also reflects a broader pattern of Chinese-headquartered biopharma companies seeking regulatory footholds in Western markets through Australia’s well-regarded review pathway. For InnoCare, Australian authorization builds a commercial and regulatory track record that can support filings elsewhere. For Australian patients and the oncologists treating them, the immediate value is access to a targeted therapy in a setting where relapsed mantle cell lymphoma offers few easy answers. Pharmaceutical Benefits Scheme listing decisions will shape how affordable that access becomes.

Source: GlobeNewswire | https://www.globenewswire.com/news-release/2026/05/27/3301710/0/en/InnoCare-Announces-Approval-of-Orelabrutinib-in-Australia.html

WHO Declares a Bundibugyo Ebola Outbreak a Global Emergency

A rapidly escalating Ebola outbreak across remote parts of the Democratic Republic of the Congo and Uganda pushed past 230 deaths and more than 900 suspected cases by May 25, prompting the World Health Organization to declare a Public Health Emergency of International Concern. The outbreak is driven by the rare Bundibugyo strain and is believed to have originated in the conflict-affected Ituri Province in northeastern DRC.

The Bundibugyo species presents a particular problem because there is no licensed vaccine or specific approved treatment for it, unlike the Zaire strain that anchored prior outbreak responses. Work to test promising candidates is underway, but the WHO warned that the epidemic is spreading faster than the response can contain it, a combination of a virulent pathogen, a fragile health infrastructure, and active conflict that complicates contact tracing and case isolation.

The international ripple effects were immediate. The CDC announced entry restrictions on non-US passport holders who had been in Uganda, the DRC, or South Sudan within the prior 21 days, and expanded enhanced airport screening to Atlanta as of May 23. Those measures echo the operational playbook of past outbreaks and signal that health authorities expect a prolonged response. For global health security, an outbreak of a strain with no countermeasure is a stress test of how quickly experimental vaccines and therapeutics can be deployed under emergency conditions, and a reminder of how much outbreak risk concentrates in regions with the least capacity to respond.

Source: World Health Organization | https://www.who.int/emergencies/situations/ebola-outbreak—drc-2026

CMS Launches Its BALANCE Model to Cap GLP-1 Costs in Medicaid

The Centers for Medicare and Medicaid Services moved to address one of the most expensive line items in American drug spending this week as its BALANCE model began rolling into Medicaid programs as early as May. The demonstration targets GLP-1 medicines, the class driving both obesity treatment and budget anxiety, and is designed so that eligible Medicare beneficiaries will eventually pay $50 for a month of GLP-1 therapy when the model reaches Medicare Part D in January 2027.

BALANCE is one piece of a wider wave of CMS pricing models taking shape in 2026. The agency has also proposed the mandatory GLOBE model for certain Part B drugs, set to run for five years beginning October 1 and covering roughly 25 percent of Medicare beneficiaries in a defined geographic area, alongside a GENEROUS model that lets CMS negotiate Medicaid prices with participating manufacturers. The activity sits on top of the ongoing Medicare Drug Price Negotiation Program, whose third cycle selected 15 high-cost drugs, including, for the first time, products payable under Part B.

The policy logic is to convert surging GLP-1 demand into negotiated, predictable spending rather than open-ended exposure. For patients, a capped monthly cost would remove a major barrier to a therapy class that has been priced out of reach for many. For manufacturers, participation trades headline price for guaranteed volume, a calculation that becomes harder to refuse as more of the federal book of business shifts toward these models. Payers and pharmacy benefit managers will be recalibrating formularies around whichever models survive the inevitable legal and political contests.

Source: CMS | https://www.cms.gov/newsroom/press-releases/cms-announces-new-drug-payment-model-strengthen-medicaid-better-serve-vulnerable-americans

Medtronic, Abbott, and Boston Scientific Present New Ablation Data at HRS 2026

The three largest names in cardiac rhythm management used the Heart Rhythm Society’s 2026 annual meeting in Chicago to put fresh pulsed-field ablation data in front of electrophysiologists, sharpening a competition that has reshaped how atrial fibrillation is treated. Medtronic presented late-breaking results from an early feasibility study within its Affera device family, examining whether the technology can prevent dangerous ventricular arrhythmias in patients who have survived a heart attack.

Abbott contributed six-month data from its FlexPulse IDE study of the TactiFlex Duo ablation catheter, reporting that 87 percent of patients remained free of documented arrhythmias at the six-month mark. Boston Scientific rounded out the field with its own portfolio data, leaving the meeting as a snapshot of how quickly pulsed-field ablation has moved from novelty to standard practice. The shift matters clinically because pulsed-field energy targets cardiac tissue while largely sparing surrounding structures such as the esophagus, a safety advantage over older thermal ablation methods.

The push into ventricular applications is the development to watch. Atrial fibrillation has been the proving ground for these devices, but extending pulsed-field ablation to ventricular arrhythmias in post-infarction patients would open a far larger and higher-acuity market. For hospitals, the competition among three well-capitalized manufacturers should keep innovation moving and give electrophysiology programs leverage on price and platform choice. For patients, the trajectory points toward safer, faster ablation procedures across a widening set of indications.

Source: Medical Device Network | https://www.medicaldevice-network.com/news/hrs-2026-medtronic-boston-scientific-abbott-pfa-clinical-trial-results/

Gilead’s Hepcludex Becomes the First Approved Hepatitis Delta Therapy in the US

The week opened on the back of a landmark regulatory decision when the FDA approved Gilead Sciences’ Hepcludex, known generically as bulevirtide, on May 22 as the first treatment for chronic hepatitis delta virus infection in US adults without cirrhosis or with compensated cirrhosis. Hepatitis D is the most aggressive form of viral hepatitis and can accelerate liver fibrosis, liver cancer, and liver failure, yet it has had no approved therapy in the country until this decision.

The agency granted accelerated approval based on reductions in HDV RNA and normalization of the liver enzyme ALT, drawing primarily on data from the pivotal Phase 3 MYR301 study. The approval carried Priority Review, Breakthrough Therapy, and Orphan Drug designations, a stack of regulatory tools reserved for serious conditions with high unmet need. Roughly 4 percent of people living with hepatitis B in the US also carry hepatitis D, which translates to about 80,000 people who now have a treatment option for the first time.

The clinical significance is hard to overstate for a disease that previously offered only off-label and supportive management. Bulevirtide works by blocking viral entry into liver cells, a first-in-class mechanism for HDV, and its arrival establishes a treatment standard where none existed. The accelerated pathway means confirmatory data will determine whether the approval becomes permanent, and access will hinge on diagnosis rates, since hepatitis D remains widely underdiagnosed among the hepatitis B population. Hepatologists now have both a reason and a tool to test more aggressively.

Source: FDA | https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-chronic-hepatitis-delta-virus-hdv-infection

Early-Stage Biotechs Close Fresh Series A Rounds Despite a Tight Market

Venture activity in life sciences kept its footing through late May, with several early-stage companies closing sizable financings even as the broader funding environment stayed selective. Princeton-based Kanvas Biosciences raised a $48 million Series A to fund clinical trials of KAN-001, its lead immuno-oncology live biotherapeutic, while Redwood City-based R1 Therapeutics launched with an oversubscribed $77.5 million Series A to develop AP306, described as a first-in-class pan phosphate transporter inhibitor.

These rounds sit against a 2026 backdrop defined by consolidation at the top and discipline below it. Medtech venture funding reached $2.2 billion across 66 rounds in the first quarter, while biopharma dealmaking accelerated as large companies raced to refill pipelines ahead of a patent cliff estimated to put roughly $170 billion of revenue at risk. In that context, investors are concentrating capital on differentiated mechanisms and clear clinical hypotheses rather than spreading bets across a crowded field.

The pattern carries a clear message for founders. Capital is available for companies with a credible first-in-class or best-in-class story, but the bar for a clean Series A has risen, and oversubscription now signals genuine conviction rather than froth. For the acquirers circling these assets, well-funded early-stage programs become the feedstock for the next wave of licensing deals and acquisitions, the same dynamic that drove Eli Lilly’s vaccine buying spree this week. The funding market and the M&A market are increasingly two ends of the same pipeline.

Source: Fierce Biotech | https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-26

CDC Widens a Salmonella Alert Tied to Moringa Leaf Products

The CDC updated a food safety alert on May 27 covering a growing number of Salmonella illnesses and outbreaks linked to moringa leaf products, the kind of investigation that rarely makes front pages but speaks directly to everyday public health risk. Moringa, marketed widely as a plant-based supplement and food additive, has surged in popularity through wellness channels, and contaminated lots can reach consumers across many states before a pattern becomes visible to investigators.

Salmonella remains one of the most common causes of foodborne illness, and outbreaks tied to dried botanical and supplement products are particularly hard to trace because the items have long shelf lives and move through diffuse retail and online distribution. The agency’s update reflects the slow, methodical work of matching genetic fingerprints of bacteria from sick people to specific product lots, a process that often expands as more cases are sequenced and linked.

The episode is a reminder that the supplement and functional-food category, lightly regulated compared with conventional pharmaceuticals, carries real contamination risk that public health agencies must manage with limited authority. For consumers, the practical guidance is to heed recall notices and treat botanical supplements with the same caution applied to any food product. For regulators, recurring outbreaks in this category strengthen the argument for tighter oversight of how plant-derived wellness products are sourced and tested before sale.

Source: CDC | https://www.cdc.gov/outbreaks/index.html

Recent Regulatory Decisions and Major Deals at a Glance

The week’s biggest moves spanned five regulatory authorities and several major companies. The table below organizes the key decisions and transactions by region and date.

Closing Perspective

The week of May 23 to 30, 2026, turned on a single theme: capital and regulation moving in the same direction as Big Pharma races to refill pipelines and health systems push therapies toward patients faster.

Watch the European Commission’s final ruling on oral semaglutide, mature survival data from this year’s ASCO oncology readouts, and the WHO’s effort to deploy experimental countermeasures against a Bundibugyo strain with no approved treatment.

Stay tuned for more of the latest healthcare news, with daily updates as these stories develop.